vs
Side-by-side financial comparison of Nutex Health, Inc. (NUTX) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.
Nutex Health, Inc. is the larger business by last-quarter revenue ($151.7M vs $83.1M, roughly 1.8× PROCEPT BioRobotics Corp). Nutex Health, Inc. runs the higher net margin — 7.8% vs -38.1%, a 45.9% gap on every dollar of revenue. On growth, PROCEPT BioRobotics Corp posted the faster year-over-year revenue change (20.2% vs -41.1%). Over the past eight quarters, Nutex Health, Inc.'s revenue compounded faster (50.0% CAGR vs 24.8%).
Nutex Health Inc. is an American for-profit health care company and operator of healthcare facilities headquartered in Houston, Texas.
PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.
NUTX vs PRCT — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $151.7M | $83.1M |
| Net Profit | $11.8M | $-31.6M |
| Gross Margin | 30.4% | 64.9% |
| Operating Margin | 20.4% | -4.1% |
| Net Margin | 7.8% | -38.1% |
| Revenue YoY | -41.1% | 20.2% |
| Net Profit YoY | -80.8% | -27.9% |
| EPS (diluted) | $2.34 | $-0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $83.1M | ||
| Q4 25 | $151.7M | $76.4M | ||
| Q3 25 | $267.8M | $83.3M | ||
| Q2 25 | $244.0M | $79.2M | ||
| Q1 25 | $211.8M | $69.2M | ||
| Q4 24 | $257.6M | $68.2M | ||
| Q3 24 | $78.8M | $58.4M | ||
| Q2 24 | $76.1M | $53.4M |
| Q1 26 | — | $-31.6M | ||
| Q4 25 | $11.8M | $-29.8M | ||
| Q3 25 | $55.4M | $-21.4M | ||
| Q2 25 | $-17.7M | $-19.6M | ||
| Q1 25 | $21.2M | $-24.7M | ||
| Q4 24 | $61.6M | $-18.9M | ||
| Q3 24 | $-8.8M | $-21.0M | ||
| Q2 24 | $-364.0K | $-25.6M |
| Q1 26 | — | 64.9% | ||
| Q4 25 | 30.4% | 60.6% | ||
| Q3 25 | 57.8% | 64.8% | ||
| Q2 25 | 51.2% | 65.4% | ||
| Q1 25 | 55.9% | 63.9% | ||
| Q4 24 | 55.0% | 64.0% | ||
| Q3 24 | 27.8% | 63.2% | ||
| Q2 24 | 29.7% | 59.0% |
| Q1 26 | — | -4.1% | ||
| Q4 25 | 20.4% | -40.6% | ||
| Q3 25 | 48.7% | -27.8% | ||
| Q2 25 | 13.8% | -28.0% | ||
| Q1 25 | 38.1% | -39.7% | ||
| Q4 24 | 44.4% | -28.9% | ||
| Q3 24 | 12.3% | -38.4% | ||
| Q2 24 | 7.0% | -50.3% |
| Q1 26 | — | -38.1% | ||
| Q4 25 | 7.8% | -39.1% | ||
| Q3 25 | 20.7% | -25.7% | ||
| Q2 25 | -7.3% | -24.7% | ||
| Q1 25 | 10.0% | -35.8% | ||
| Q4 24 | 23.9% | -27.6% | ||
| Q3 24 | -11.2% | -35.9% | ||
| Q2 24 | -0.5% | -48.0% |
| Q1 26 | — | $-0.56 | ||
| Q4 25 | $2.34 | $-0.54 | ||
| Q3 25 | $7.76 | $-0.38 | ||
| Q2 25 | $-2.95 | $-0.35 | ||
| Q1 25 | $3.33 | $-0.45 | ||
| Q4 24 | $11.56 | $-0.34 | ||
| Q3 24 | $-1.72 | $-0.40 | ||
| Q2 24 | $-0.07 | $-0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $185.6M | $245.6M |
| Total DebtLower is stronger | — | $51.7M |
| Stockholders' EquityBook value | $329.4M | $347.7M |
| Total Assets | $918.5M | $487.1M |
| Debt / EquityLower = less leverage | — | 0.15× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $245.6M | ||
| Q4 25 | $185.6M | $286.5M | ||
| Q3 25 | $166.0M | $294.3M | ||
| Q2 25 | $96.7M | $302.7M | ||
| Q1 25 | $84.7M | $316.2M | ||
| Q4 24 | $40.6M | $333.7M | ||
| Q3 24 | $46.9M | $196.8M | ||
| Q2 24 | $40.8M | $214.1M |
| Q1 26 | — | $51.7M | ||
| Q4 25 | — | $51.6M | ||
| Q3 25 | — | $51.6M | ||
| Q2 25 | — | $51.5M | ||
| Q1 25 | — | $51.5M | ||
| Q4 24 | — | $51.5M | ||
| Q3 24 | — | $51.4M | ||
| Q2 24 | — | $51.4M |
| Q1 26 | — | $347.7M | ||
| Q4 25 | $329.4M | $365.9M | ||
| Q3 25 | $317.2M | $380.3M | ||
| Q2 25 | $235.3M | $385.8M | ||
| Q1 25 | $176.9M | $389.2M | ||
| Q4 24 | $132.4M | $402.2M | ||
| Q3 24 | $60.4M | $241.2M | ||
| Q2 24 | $62.7M | $251.8M |
| Q1 26 | — | $487.1M | ||
| Q4 25 | $918.5M | $508.1M | ||
| Q3 25 | $964.5M | $511.5M | ||
| Q2 25 | $841.0M | $513.1M | ||
| Q1 25 | $761.9M | $519.4M | ||
| Q4 24 | $655.3M | $534.0M | ||
| Q3 24 | $438.5M | $374.1M | ||
| Q2 24 | $422.4M | $374.4M |
| Q1 26 | — | 0.15× | ||
| Q4 25 | — | 0.14× | ||
| Q3 25 | — | 0.14× | ||
| Q2 25 | — | 0.13× | ||
| Q1 25 | — | 0.13× | ||
| Q4 24 | — | 0.13× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.20× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $70.4M | — |
| Free Cash FlowOCF − Capex | $69.0M | — |
| FCF MarginFCF / Revenue | 45.5% | — |
| Capex IntensityCapex / Revenue | 0.9% | — |
| Cash ConversionOCF / Net Profit | 5.95× | — |
| TTM Free Cash FlowTrailing 4 quarters | $245.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $70.4M | $-10.3M | ||
| Q3 25 | $99.5M | $-6.6M | ||
| Q2 25 | $27.3M | $-15.0M | ||
| Q1 25 | $51.0M | $-17.0M | ||
| Q4 24 | $54.0K | $-32.4M | ||
| Q3 24 | $6.8M | $-18.8M | ||
| Q2 24 | $13.3M | $-15.7M |
| Q1 26 | — | — | ||
| Q4 25 | $69.0M | $-12.2M | ||
| Q3 25 | $99.2M | $-9.5M | ||
| Q2 25 | $26.5M | $-17.8M | ||
| Q1 25 | $50.9M | $-18.8M | ||
| Q4 24 | $-341.0K | $-33.6M | ||
| Q3 24 | $6.2M | $-19.0M | ||
| Q2 24 | $12.7M | $-16.8M |
| Q1 26 | — | — | ||
| Q4 25 | 45.5% | -15.9% | ||
| Q3 25 | 37.0% | -11.4% | ||
| Q2 25 | 10.9% | -22.5% | ||
| Q1 25 | 24.0% | -27.2% | ||
| Q4 24 | -0.1% | -49.2% | ||
| Q3 24 | 7.8% | -32.6% | ||
| Q2 24 | 16.7% | -31.4% |
| Q1 26 | — | — | ||
| Q4 25 | 0.9% | 2.4% | ||
| Q3 25 | 0.1% | 3.4% | ||
| Q2 25 | 0.3% | 3.5% | ||
| Q1 25 | 0.0% | 2.7% | ||
| Q4 24 | 0.2% | 1.7% | ||
| Q3 24 | 0.8% | 0.4% | ||
| Q2 24 | 0.7% | 2.0% |
| Q1 26 | — | — | ||
| Q4 25 | 5.95× | — | ||
| Q3 25 | 1.80× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 2.40× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
PRCT
| Handpieces and other consumables | $43.0M | 52% |
| System sales and rentals | $23.4M | 28% |
| Other | $11.1M | 13% |
| Service | $5.6M | 7% |
